Evidence for covalent binding of adriamycin to rat liver microsomal proteins

Pietro Ghezzi; Maria Grazia Donelli; Claudio Pantarotto; Terenzio Facchinetti; Silvio Garattini

doi:10.1016/0006-2952(81)90191-X

Evidence for covalent binding of adriamycin to rat liver microsomal proteins

Pietro Ghezzi, Maria Grazia Donelli, Claudio Pantarotto, Terenzio Facchinetti, Silvio Garattini

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article

Abstract

Adriamycin (NSC-123, 127) is an anticancer drug of the anthracycline type widely used in the clinical practice for the treatment of different malignancies (1). Intercalation with DNA has been suggested as having a role in the mechanism of action of this drug (2, 3, 4). Recently, reports by Sinha (5) and Lucacchini et al. (6) suggested a covalent interaction of Adriamycin (AM) with DNA and proteins. These studies, however, were not conclusive since they were carried out by spectrophotometric and Chromatographie procedures. In the present study a covalent interaction between AM and microsomal proteins was demonstrated in a more "classical" covalent binding study with the ¹⁴C-labelled compound.

Original language	English
Pages (from-to)	175-177
Number of pages	3
Journal	Biochemical Pharmacology
Volume	30
Issue number	2
DOIs	https://doi.org/10.1016/0006-2952(81)90191-X
Publication status	Published - Jan 15 1981

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/0006-2952(81)90191-X

Fingerprint Dive into the research topics of 'Evidence for covalent binding of adriamycin to rat liver microsomal proteins'. Together they form a unique fingerprint.

Cite this

Ghezzi, P., Donelli, M. G., Pantarotto, C., Facchinetti, T., & Garattini, S. (1981). Evidence for covalent binding of adriamycin to rat liver microsomal proteins. Biochemical Pharmacology, 30(2), 175-177. https://doi.org/10.1016/0006-2952(81)90191-X

@article{4a8051b8366e470286d4439d157ed369,

title = "Evidence for covalent binding of adriamycin to rat liver microsomal proteins",

abstract = "Adriamycin (NSC-123, 127) is an anticancer drug of the anthracycline type widely used in the clinical practice for the treatment of different malignancies (1). Intercalation with DNA has been suggested as having a role in the mechanism of action of this drug (2, 3, 4). Recently, reports by Sinha (5) and Lucacchini et al. (6) suggested a covalent interaction of Adriamycin (AM) with DNA and proteins. These studies, however, were not conclusive since they were carried out by spectrophotometric and Chromatographie procedures. In the present study a covalent interaction between AM and microsomal proteins was demonstrated in a more {"}classical{"} covalent binding study with the 14C-labelled compound.",

author = "Pietro Ghezzi and Donelli, {Maria Grazia} and Claudio Pantarotto and Terenzio Facchinetti and Silvio Garattini",

year = "1981",

month = jan,

day = "15",

doi = "10.1016/0006-2952(81)90191-X",

language = "English",

volume = "30",

pages = "175--177",

journal = "Biochemical Pharmacology",

issn = "0006-2952",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Evidence for covalent binding of adriamycin to rat liver microsomal proteins

AU - Ghezzi, Pietro

AU - Donelli, Maria Grazia

AU - Pantarotto, Claudio

AU - Facchinetti, Terenzio

AU - Garattini, Silvio

PY - 1981/1/15

Y1 - 1981/1/15

N2 - Adriamycin (NSC-123, 127) is an anticancer drug of the anthracycline type widely used in the clinical practice for the treatment of different malignancies (1). Intercalation with DNA has been suggested as having a role in the mechanism of action of this drug (2, 3, 4). Recently, reports by Sinha (5) and Lucacchini et al. (6) suggested a covalent interaction of Adriamycin (AM) with DNA and proteins. These studies, however, were not conclusive since they were carried out by spectrophotometric and Chromatographie procedures. In the present study a covalent interaction between AM and microsomal proteins was demonstrated in a more "classical" covalent binding study with the 14C-labelled compound.

AB - Adriamycin (NSC-123, 127) is an anticancer drug of the anthracycline type widely used in the clinical practice for the treatment of different malignancies (1). Intercalation with DNA has been suggested as having a role in the mechanism of action of this drug (2, 3, 4). Recently, reports by Sinha (5) and Lucacchini et al. (6) suggested a covalent interaction of Adriamycin (AM) with DNA and proteins. These studies, however, were not conclusive since they were carried out by spectrophotometric and Chromatographie procedures. In the present study a covalent interaction between AM and microsomal proteins was demonstrated in a more "classical" covalent binding study with the 14C-labelled compound.

UR - http://www.scopus.com/inward/record.url?scp=0019364997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019364997&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(81)90191-X

DO - 10.1016/0006-2952(81)90191-X

M3 - Article

C2 - 7236308

AN - SCOPUS:0019364997

VL - 30

SP - 175

EP - 177

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 2

ER -